about
Potential viral pathogenic mechanism for new variant inflammatory bowel diseaseMolecular pathology of prostate cancerNon-invasive and non-destructive measurements of confluence in cultured adherent cell linesResistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoproteinReal-time analysis of beta- and gamma-catenin mRNA expression in ret/PTC-1 activated and nonactivated thyroid tissues.A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples.Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients.The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy.Cellular localisation of HHV-8 in Castleman's disease: is there a link with lymph node vascularity?"If you can't treat HPV, why test for it?" Women's attitudes to the changing face of cervical cancer prevention: a focus group studyPlatelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.An integrated analysis of the SOX2 microRNA response program in human pluripotent and nullipotent stem cell lines.MIR141 Expression Differentiates Hashimoto Thyroiditis from PTC and Benign Thyrocytes in Irish Archival Thyroid Tissues.Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention.p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears.Towards a "Sample-In, Answer-Out" Point-of-Care Platform for Nucleic Acid Extraction and Amplification: Using an HPV E6/E7 mRNA Model SystemIdentifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.Endosomal gene expression: a new indicator for prostate cancer patient prognosis?Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancerAltered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression.Increased platelet reactivity in patients with late-stage metastatic cancer.Evaluation of the clinical performance of the cobas 4800 HPV test in patients referred for colposcopyHuman papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study.Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention.MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotypeAssessment of the humoral immune response to cancer.Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.Molecular testing in oncology: problems, pitfalls and progress.The use of MYBL2 as a novel candidate biomarker of cervical cancer.Cytokeratin 7 in Oropharyngeal Squamous Cell Carcinoma: A Junctional Biomarker for Human Papillomavirus-Related Tumors.Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening.Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease: A systematic review.The Value of a Novel Panel of Cervical Cancer Biomarkers for Triage of HPV Positive Patients and for Detecting Disease Progression.Enhanced regulation of cell cycle and suppression of osteoblast differentiation molecular signatures by prostate cancer stem-like holoclones.PARP Inhibitors as P-glyoprotein Substrates.Human papillomavirus DNA and mRNA prevalence and association with cervical cytological abnormalities in the Irish HIV population.Global mRNA analysis to determine a transcriptome profile of cancer stemness in a mouse model.
P50
Q24535473-12C2E405-9099-4F8A-9E15-DAEE07168D72Q24672410-ED5E8F8F-67E9-44D0-B05F-F744F2AB9F14Q28364951-C4DB34E9-AAEC-485E-A10D-73E96123CA70Q28481246-3014D702-71EB-4556-8447-16383E2589CBQ31133084-640A91CD-0D8B-4304-945D-410281EDF0FFQ33292141-87E8514B-E872-4B3B-8F59-38432386B1E3Q33587316-949C29C8-47EE-41C6-8B8F-DAB452873449Q33825555-59D0E179-A031-4D00-B4DC-A683CD2FDEF8Q33899570-FBCB2FB3-7354-46EA-8601-CAA3AB4DCC4AQ33918443-84A29784-AB2D-44D1-A9ED-CF624335BF3BQ34055333-BCACE0EC-C970-47CB-8548-368992CC8447Q34056033-5DDC170F-F8A2-4985-8E31-F6883FEBF636Q34174419-033B63B7-CBE4-4560-982C-C81103FA86A5Q34411905-14083E41-4D9C-46B0-8C3A-877F20EB6128Q34562736-77A086F9-2A88-43F1-B802-263E5C89D946Q34968735-1A48B194-B83E-44AE-BDAC-F8A1AF7FEE54Q35586592-3B048F39-BA60-4823-9A99-A882861811D3Q35660073-743609C7-7A84-48D0-BA7F-2C74711029CDQ35709343-670A6FD8-D761-463E-AB4B-57363D2019C7Q35768450-4C3E3A73-0056-432F-BC8B-46EE795B6510Q36545920-516CB76A-C8E7-4C70-8DCE-90270D8F4C91Q36670959-91B6BC88-5D6D-4437-8AE0-D524916E9E8CQ37071712-40CD27FA-8523-49B8-9F06-62F8EC6328C2Q37236283-E42201DE-8A0E-418E-A4FF-7B0C97CF1766Q37264293-02A3B9F5-79B2-402F-8C13-E6C3996DC21DQ37279345-A73EE930-9E9B-4EBA-8B32-8183F0FEBE4EQ37661508-A0BDF174-857B-4437-AEBC-C5C0F3790547Q37706921-5D364858-70AC-4359-900F-3854D5A7D8C6Q37980913-0D212787-1D60-47AB-8262-F62A6A84D3ADQ38023288-786B8C12-DA27-45BD-A101-3F402FF40F40Q38182743-2EEF4261-FCF8-49FE-84A0-C0C9CDCC04C1Q38263049-9FFF4F2C-B16D-4960-882B-3F3A98BE9FCEQ38376388-B9B7275A-3487-49FF-AA95-685271B2BCF1Q38674438-3E016B96-AB0A-404E-AF81-753C3E8494F4Q38707755-1ED19478-34FA-4892-BE6A-772DEFD8A524Q38753469-9A5E7B18-182D-4608-9CF4-043E2F0C7A47Q38868077-ACA6F654-67D7-4BBA-AFBA-5819413531C4Q39008101-9FFA107D-8D14-4C44-89FC-7D47109CC4A9Q39122816-FCB94AF6-D12C-4EFE-917A-F74E012F5848Q40115067-5742A0A5-639D-4D89-8B52-13C45DFB3EE0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
John O'Leary
@ast
John O'Leary
@en
John O'Leary
@es
John O'Leary
@nl
type
label
John O'Leary
@ast
John O'Leary
@en
John O'Leary
@es
John O'Leary
@nl
prefLabel
John O'Leary
@ast
John O'Leary
@en
John O'Leary
@es
John O'Leary
@nl
P108
P106
P21
P31
P496
0000-0001-7311-9326